Concomitant tumor and minor histocompatibility antigen-specific immunity initiate rejection and maintain remission from established spontaneous solid tumors

Rodrigo Hess Michelini, Massimo Freschi, Teresa Manzo, Elena Jachetti, Elena Degl'Innocenti, Matteo Grioni, Veronica Basso, Chiara Bonini, Elizabeth Simpson, Anna Mondino, Matteo Bellone

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Nonmyeloablative hematopoietic cell transplantation can cure patients with hematologic malignancies but has reported limited success against solid tumors. This is possibly because of profound peripheral tolerance mechanisms and/or suboptimal tumor recognition by effector T lymphocytes. We report that in mice developing spontaneous prostate cancer, nonmyeloablative minor histocompatibility mismatched hematopoietic stem cell transplantation, and donor lymphocyte infusion of unmanipulated lymphocytes combined with posttransplant tumor-specific vaccination circumvents tumor-specific tolerance, allowing acute tumor rejection and the establishment of protective immunosurveillance. Although donor-derived tumor-specific T cells readily differentiated into effector cells and infiltrated the tumor soon after infusion, they were alone insufficient for tumor eradication, which instead required the concomitance of minor histocompatibiltiy antigen-specific CD8+ T-cell responses. The establishment of protective immunosurveillance was best induced by posttransplant tumor-specific vaccination. Hence, these results provide the proof of principle that tumor-specific T-cell responses have to be harnessed together with minor histocompatibility responses and sustained by posttransplant tumor-specific vaccination to improve the efficacy of allotransplantion for the cure of solid tumors.

Original languageEnglish
Pages (from-to)3505-3514
Number of pages10
JournalCancer Research
Volume70
Issue number9
DOIs
Publication statusPublished - May 1 2010

Fingerprint

Minor Histocompatibility Antigens
Spontaneous Remission
Immunity
Neoplasms
T-Lymphocytes
Immunologic Monitoring
Vaccination
Histocompatibility
Tissue Donors
Lymphocytes
Peripheral Tolerance
CD8 Antigens
Hematopoietic Stem Cell Transplantation
Cell Transplantation
Hematologic Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Concomitant tumor and minor histocompatibility antigen-specific immunity initiate rejection and maintain remission from established spontaneous solid tumors. / Michelini, Rodrigo Hess; Freschi, Massimo; Manzo, Teresa; Jachetti, Elena; Degl'Innocenti, Elena; Grioni, Matteo; Basso, Veronica; Bonini, Chiara; Simpson, Elizabeth; Mondino, Anna; Bellone, Matteo.

In: Cancer Research, Vol. 70, No. 9, 01.05.2010, p. 3505-3514.

Research output: Contribution to journalArticle

Michelini, Rodrigo Hess ; Freschi, Massimo ; Manzo, Teresa ; Jachetti, Elena ; Degl'Innocenti, Elena ; Grioni, Matteo ; Basso, Veronica ; Bonini, Chiara ; Simpson, Elizabeth ; Mondino, Anna ; Bellone, Matteo. / Concomitant tumor and minor histocompatibility antigen-specific immunity initiate rejection and maintain remission from established spontaneous solid tumors. In: Cancer Research. 2010 ; Vol. 70, No. 9. pp. 3505-3514.
@article{473dc238909a429bb6792b3f7a1c0ea9,
title = "Concomitant tumor and minor histocompatibility antigen-specific immunity initiate rejection and maintain remission from established spontaneous solid tumors",
abstract = "Nonmyeloablative hematopoietic cell transplantation can cure patients with hematologic malignancies but has reported limited success against solid tumors. This is possibly because of profound peripheral tolerance mechanisms and/or suboptimal tumor recognition by effector T lymphocytes. We report that in mice developing spontaneous prostate cancer, nonmyeloablative minor histocompatibility mismatched hematopoietic stem cell transplantation, and donor lymphocyte infusion of unmanipulated lymphocytes combined with posttransplant tumor-specific vaccination circumvents tumor-specific tolerance, allowing acute tumor rejection and the establishment of protective immunosurveillance. Although donor-derived tumor-specific T cells readily differentiated into effector cells and infiltrated the tumor soon after infusion, they were alone insufficient for tumor eradication, which instead required the concomitance of minor histocompatibiltiy antigen-specific CD8+ T-cell responses. The establishment of protective immunosurveillance was best induced by posttransplant tumor-specific vaccination. Hence, these results provide the proof of principle that tumor-specific T-cell responses have to be harnessed together with minor histocompatibility responses and sustained by posttransplant tumor-specific vaccination to improve the efficacy of allotransplantion for the cure of solid tumors.",
author = "Michelini, {Rodrigo Hess} and Massimo Freschi and Teresa Manzo and Elena Jachetti and Elena Degl'Innocenti and Matteo Grioni and Veronica Basso and Chiara Bonini and Elizabeth Simpson and Anna Mondino and Matteo Bellone",
year = "2010",
month = "5",
day = "1",
doi = "10.1158/0008-5472.CAN-09-4253",
language = "English",
volume = "70",
pages = "3505--3514",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Concomitant tumor and minor histocompatibility antigen-specific immunity initiate rejection and maintain remission from established spontaneous solid tumors

AU - Michelini, Rodrigo Hess

AU - Freschi, Massimo

AU - Manzo, Teresa

AU - Jachetti, Elena

AU - Degl'Innocenti, Elena

AU - Grioni, Matteo

AU - Basso, Veronica

AU - Bonini, Chiara

AU - Simpson, Elizabeth

AU - Mondino, Anna

AU - Bellone, Matteo

PY - 2010/5/1

Y1 - 2010/5/1

N2 - Nonmyeloablative hematopoietic cell transplantation can cure patients with hematologic malignancies but has reported limited success against solid tumors. This is possibly because of profound peripheral tolerance mechanisms and/or suboptimal tumor recognition by effector T lymphocytes. We report that in mice developing spontaneous prostate cancer, nonmyeloablative minor histocompatibility mismatched hematopoietic stem cell transplantation, and donor lymphocyte infusion of unmanipulated lymphocytes combined with posttransplant tumor-specific vaccination circumvents tumor-specific tolerance, allowing acute tumor rejection and the establishment of protective immunosurveillance. Although donor-derived tumor-specific T cells readily differentiated into effector cells and infiltrated the tumor soon after infusion, they were alone insufficient for tumor eradication, which instead required the concomitance of minor histocompatibiltiy antigen-specific CD8+ T-cell responses. The establishment of protective immunosurveillance was best induced by posttransplant tumor-specific vaccination. Hence, these results provide the proof of principle that tumor-specific T-cell responses have to be harnessed together with minor histocompatibility responses and sustained by posttransplant tumor-specific vaccination to improve the efficacy of allotransplantion for the cure of solid tumors.

AB - Nonmyeloablative hematopoietic cell transplantation can cure patients with hematologic malignancies but has reported limited success against solid tumors. This is possibly because of profound peripheral tolerance mechanisms and/or suboptimal tumor recognition by effector T lymphocytes. We report that in mice developing spontaneous prostate cancer, nonmyeloablative minor histocompatibility mismatched hematopoietic stem cell transplantation, and donor lymphocyte infusion of unmanipulated lymphocytes combined with posttransplant tumor-specific vaccination circumvents tumor-specific tolerance, allowing acute tumor rejection and the establishment of protective immunosurveillance. Although donor-derived tumor-specific T cells readily differentiated into effector cells and infiltrated the tumor soon after infusion, they were alone insufficient for tumor eradication, which instead required the concomitance of minor histocompatibiltiy antigen-specific CD8+ T-cell responses. The establishment of protective immunosurveillance was best induced by posttransplant tumor-specific vaccination. Hence, these results provide the proof of principle that tumor-specific T-cell responses have to be harnessed together with minor histocompatibility responses and sustained by posttransplant tumor-specific vaccination to improve the efficacy of allotransplantion for the cure of solid tumors.

UR - http://www.scopus.com/inward/record.url?scp=77951764520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951764520&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-09-4253

DO - 10.1158/0008-5472.CAN-09-4253

M3 - Article

VL - 70

SP - 3505

EP - 3514

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 9

ER -